🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

123 results for “Sanofi” Clear

  1. Matched placebo for test product, Duvakitug

    Sanofi Pharma Bristol-Myers Squibb

    Immune system disseases

    phase 3 small molecule active

    1 trial

  2. Matched placebo for test product, Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  3. Matched placebo for test product, Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  4. Matched placebo for test product, Itepekimab

    Sanofi Pharma Bristol-Myers Squibb

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  5. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine

    Sanofi Pasteur

    Meningococcal infection

    phase 3 small molecule active

    1 trial

  6. Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion, avalglucosidase alfa, Nexviadyme 100 mg powder for concentrate for solution for infusion, Nexviadyme 100 mg powder for concentrate for solution for infusion

    Sanofi Pharma Bristol-Myers Squibb

    Glycogen storage disease type II

    phase 3 small molecule active

    1 trial

  7. Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Nimenrix powder and s

    Sanofi Pasteur

    Healthy volunteers (Meningococcal infection)

    phase 3 small molecule active

    1 trial

  8. PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  9. PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  10. PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)

    Sanofi Pharma Bristol-Myers Squibb

    Pneumococcal immunisation

    phase 3 small molecule active

    1 trial

  11. Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

    Sanofi Pharma Bristol-Myers Squibb

    Fabry Disease

    phase 3 small molecule active

    1 trial

  12. Prograft 5 mg capsules, hard, Prograf 0,5 mg Hartkapseln, Prograf 1 mg Hartkapseln, Frexalimab, Prograft 0,5 mg capsules, hard, Prograft 1 mg capsules, hard, Prograf 5 mg Hartkapseln

    Sanofi Pharma Bristol-Myers Squibb

    Kidney transplant rejection

    phase 3 small molecule active

    1 trial

  13. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi Pharma Bristol-Myers Squibb

    multiple sclerosis

    phase 3 other active

    1 trial

  14. Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

    Sanofi Pharma Bristol-Myers Squibb

    Non-small cell lung cancer metastatic

    phase 3 other active

    1 trial

  15. Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa

    Sanofi Pharma Bristol-Myers Squibb

    Plasma cell myeloma

    phase 3 small molecule active

    1 trial

  16. Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 3 small molecule active

    1 trial

  17. Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  18. SAR439774, SAR439774

    Sanofi Pharma Bristol-Myers Squibb

    Hemophilia

    phase 3 small molecule active

    1 trial

  19. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  20. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

  21. Teplizumab, Matched placebo for test product

    Sanofi Pharma Bristol-Myers Squibb

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  22. Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)

    Sanofi Pharma Bristol-Myers Squibb

    Pneumococcal Immunization

    phase 3 small molecule active

    1 trial

  23. matched placebo for test product, Duvakitug

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 small molecule active

    1 trial

  24. riliprubart

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources